A randomised, double-blind, placebo-controlled, multiple dose, time-lagged parallel groups trial, investigating the pharmacodynamics, the safety and tolerability and the pharmacokinetics of PSN9301 in type 2 diabetes patients - Not available
2007-04-01·Current opinion in investigational drugs (London, England : 2000)
Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
Review
作者: Epstein, Benjamin J
(OSI) Prosidion is developing PSN-9301, a rationally designed dipeptidyl peptidase IV inhibitor acquired from Probiodrug AG, as a potential oral treatment for type 2 diabetes. Phase II clinical trials of PSN-9301 are underway.